Allogene Therapeutics Inc. Common Stock (ALLO)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor first: I want durable earnings, a conservative balance sheet, and a price that leaves a margin of safety. Allogene is a clinical-stage immuno-oncology company with 150 employees, developing allogeneic CAR T therapies; it has no meaningful product profits yet. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $4.6M, net income of -$42.7M, and diluted EPS of -$0.13. That is a net margin of -919.76%, and trailing free cash flow was -$102.6M, or a FairStock FCF yield of -23.0%. Losses are narrowing: FY2023 net income was -$327.3M, FY2024 was -$257.6M, and FY2025 was -$190.9M, but the company remains deeply unprofitable. On FairStock's calculations at the 2026-10-13 close of $1.29, the P/E is -1.95, P/B is 1.02, ROE is -42.39%, ROCE is -22.08%, and debt-to-equity is 0.18. The low debt is a positive, and P/B near 1.02 may hint at asset value, but the Piotroski F-Score of 3/9 and Altman Z-Score of -2.59 show financial fragility. FairStock's Lynch category is none because the company lost money in each of the last four years, and its FairStock Score is 64/100. A beta of 0.48 does not make a cash-burning biotech safe. The 52-week range of $1.04-$4.46 shows how volatile sentiment has been. Without earnings, intrinsic value depends on cema-cel and the pipeline succeeding in trials. That could be a lottery ticket, but it is not a Graham-style bargain with a margin of safety.

In plain English: Allogene is a small biotech testing new cancer treatments made from donor immune cells. It has no steady profits, loses money, and burns cash, though it has little debt and trades near its accounting value. At $1.29, the price looks speculative rather than clearly cheap or expensive because the future depends on trials, not current earnings.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer